European Osteoarthritis Therapeutics Market
European Osteoarthritis Therapeutics Market Size, Share and Trends Analysis Report by Anatomy (Knee Osteoarthritis, Ankle and Foot Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, Spine Osteoarthritis, and Others), by Drug Type (NSAIDs, Corticosteroids, Analgesics, Opioid Analgesics, Biologics, Viscosupplementation Agents, Regenerative Medicine and Therapies, and Others), Forecast Period, 2026–2035
Industry Overview
European osteoarthritis therapeutics market was valued at $3,304.0 million in 2025 and is projected to reach $7,052.1 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). The European osteoarthritis therapeutics market is showing steady growth, supported by an aging population, high disease awareness, and strong access to orthopedic and rheumatology care across major economies. Knee and hip osteoarthritis account for the largest share of treated cases, reflecting high prevalence and earlier diagnosis, particularly in Western Europe. NSAIDs, analgesics, and corticosteroids continue to be widely prescribed for symptom control, although long-term safety concerns are shaping more selective use. Demand for viscosupplementation agents remains strong, especially for knee osteoarthritis, as clinicians aim to delay or avoid surgical intervention. At the same time, biologics and regenerative medicine therapies are gaining traction, supported by growing clinical evidence, specialized treatment centers, and patient preference for non-surgical options. Expanding clinical research activity, coupled with structured reimbursement frameworks in countries such as Germany, France, and the Nordics, is supporting the adoption of both established and emerging therapies. Ongoing innovation from pharmaceutical and biotech players, along with healthcare system modernization, continues to reinforce the market’s long-term growth outlook across Europe.
Market Dynamics
Rising Burden of Degenerative Joint Disorders and Aging Population
Osteoarthritis prevalence continues to rise across Europe, largely driven by population aging, longer life expectancy, and increasing rates of obesity and sedentary lifestyles. Knee and hip osteoarthritis represent the most commonly treated anatomical segments, generating sustained demand for long-term symptom management and disease-modifying approaches. Early diagnosis and routine monitoring in primary and specialty care settings are increasing treatment uptake across both hospital and outpatient channels. This demographic and epidemiological shift is reinforcing consistent demand for osteoarthritis therapeutics across major European markets.
Shift Toward Non-Surgical and Advanced Pharmacological Therapies
European clinicians are increasingly prioritizing non-surgical treatment pathways to manage osteoarthritis and delay joint replacement procedures. NSAIDs, analgesics, and corticosteroids remain core treatment options, although concerns around long-term use are encouraging more tailored prescribing. Viscosupplementation agents continue to see strong adoption, particularly for knee osteoarthritis, supported by established reimbursement pathways in several countries. At the same time, biologics and regenerative medicine therapies are gaining momentum, driven by expanding clinical evidence, specialized orthopedic centers, and growing patient interest in innovative, less invasive therapies. Ongoing pharmaceutical innovation and structured healthcare systems are supporting steady market expansion across the region.
Market Segmentation
- Based on anatomy, the market is segmented into knee osteoarthritis, ankle and foot osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, spine osteoarthritis, and others.
- Based on drug type, the market is segmented into NSAIDs, corticosteroids, analgesics, opioid analgesics, biologics, viscosupplementation agents, regenerative medicine therapies, and others.
Knee Osteoarthritis Leading Treatment Demand
Knee osteoarthritis therapeutics represent the largest treated sub-segment within the European osteoarthritis therapeutics market, driven by high prevalence, early symptom onset, and significant impact on mobility and quality of life. Treatment demand is supported by frequent diagnosis in primary care and orthopedic settings, particularly among aging and overweight populations. NSAIDs, analgesics, and viscosupplementation agents are widely used to manage pain and delay surgical intervention. Strong clinical familiarity and established reimbursement pathways across Europe continue to reinforce the dominance of this segment.
Biologics and Regenerative Therapies Gaining Momentum
The drug type landscape is seeing biologics and regenerative medicine therapies emerge as the fastest-growing sub-segments, reflecting a clear shift toward advanced and non-surgical treatment options. Growing clinical research activity, expansion of private orthopedic and sports medicine clinics, and increasing patient willingness to try innovative therapies are supporting wider adoption. Companies are investing in next-generation biologics, cell-based therapies, and injectable regenerative solutions focused on improving symptom control and functional outcomes. Momentum is expected to strengthen as clinical evidence expands and regulatory pathways become more defined across key European markets.
Regional Outlook
The European osteoarthritis therapeutics market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.
Germany Dominates the Market with a Major Share
Germany stands out as a leading country in the European osteoarthritis therapeutics market, supported by a large aging population, high diagnosis rates, and strong access to orthopedic and rheumatology care. Structured statutory health insurance coverage enables broad patient access to NSAIDs, analgesics, corticosteroids, and viscosupplementation therapies, driving steady treatment volumes. The country also shows early adoption of advanced therapies, including biologics and regenerative medicine, supported by specialized clinics and active clinical research. Strong domestic pharmaceutical manufacturing, clear regulatory pathways, and emphasis on evidence-based treatment guidelines continue to position Germany as a key contributor to overall market growth.
Market Players Outlook
The major companies operating in the European osteoarthritis therapeutics market include Pfizer Inc., Johnson & Johnson, Novartis AG, Sanofi, AbbVie Inc., and Zimmer Biomet, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In December 2025, Swedish biopharmaceutical company Sobi entered into a definitive agreement to acquire Arthrosi Therapeutics, a late-stage biotech firm developing the investigational therapy pozdeutinurad, strengthening its specialty care pipeline and expanding its presence in inflammatory joint disease treatment.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the European osteoarthritis therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- European Osteoarthritis Therapeutics Market Sales Analysis – Anatomy | Drug Type ($ Million)
- European Osteoarthritis Therapeutics Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key European Osteoarthritis Therapeutics Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the European Osteoarthritis Therapeutics Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For European Osteoarthritis Therapeutics Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For European Osteoarthritis Therapeutics Market: Impact Analysis
- Market Opportunities
- Opportunities For European Osteoarthritis Therapeutics Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – European Osteoarthritis Therapeutics Market Revenue and Share by Manufacturers
- European Osteoarthritis Therapeutics Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bayer AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Haleon Plc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Kenvue Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Pfizer Inc.
- Key Company Analysis
- European Osteoarthritis Therapeutics Market Sales Analysis by Anatomy ($ Million)
- Knee Osteoarthritis
- Ankle and Foot Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Spine Osteoarthritis
- Others
- European Osteoarthritis Therapeutics Market Sales Analysis by Drug Type ($ Million)
- NSAIDs
- Corticosteroids
- Analgesics
- Opioid Analgesics
- Biologics
- Viscosupplementation Agents
- Regenerative Medicine/ Therapies
- Others
- Regional Analysis
- European Osteoarthritis Therapeutics Market Sales Analysis – Anatomy | Drug Type | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Company Profiles
- Anika Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Anika Therapeutics, Inc.
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chiesi Farmaceutici S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Egis Pharmaceuticals Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ferring Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fidia Farmaceutici S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GSK plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Grünenthal GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- IBSA SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- KRKA d.d.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Menarini Group S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Orion Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Perrigo Co. Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reckitt Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Recordati S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sandoz AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Smith & Nephew Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- STADA Arzneimittel AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
1. European Osteoarthritis Therapeutics Market Research and Analysis by Anatomy, 2025–2035 ($ Million)
2. European Knee Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
3. European Ankle and Foot Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
4. European Hip Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
5. European Shoulder Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
6. European Spine Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
7. European Other Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
8. European Osteoarthritis Therapeutics Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
9. European NSAIDs for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
10. European Corticosteroids for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
11. European Analgesics for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
12. European Opioid Analgesics for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
13. European Biologics for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
14. European Viscosupplementation Agents for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
15. European Regenerative Medicine and Therapies for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
16. European Other Drugs for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
17. European Osteoarthritis Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)
1. European Osteoarthritis Therapeutics Market Share by Anatomy, 2025 Vs 2035 (%)
2. European Knee Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
3. European Ankle and Foot Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
4. European Hip Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
5. European Shoulder Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
6. European Spine Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
7. European Other Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
8. European Osteoarthritis Therapeutics Market Share by Drug Type, 2025 Vs 2035 (%)
9. European NSAIDs for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
10. European Corticosteroids for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
11. European Analgesics for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
12. European Opioid Analgesics for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
13. European Biologics for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
14. European Viscosupplementation Agents for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
15. European Regenerative Medicine and Therapies for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
16. European Others for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
17. European Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
18. UK Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
19. France Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
20. Germany Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
21. Italy Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
22. Spain Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
23. Russia Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
24. Rest of Europe Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
